Sarepta, a leading biopharmaceutical company, disclosed preliminary total net product revenue of $369.6 million for the fourth quarter of 2025 and $1.86 billion for the entire year.
During the same period, ELEVIDYS, one of Sarepta's key products, generated $110.4 million in net product revenue in Q4 and contributed significantly with $898.7 million for the full year.
The company's PMO net product revenues amounted to $259.2 million in the fourth quarter and reached $965.6 million for the full fiscal year of 2025.
Challenges Overcome
Despite facing obstacles in 2025, Sarepta achieved a remarkable milestone by generating $1.86 billion in total net product revenue, with ELEVIDYS being a major contributor with $898.7 million in revenue.
Financial Strength
Sarepta wrapped up the year with a robust financial position, boasting approximately $953.8 million in cash, cash equivalents, restricted cash, and investments. This strong liquidity provides the company with the necessary resources to invest in its existing approved therapies and advance its pipeline of innovative treatments.
2026 Initiatives
In the upcoming year, Sarepta is focusing on key initiatives to sustain the success of its approved therapies, particularly ELEVIDYS. The company aims to surpass its sales target of $500.0 million, highlighting its commitment to driving growth and innovation.
- Sarepta's exceptional performance in 2025, surpassing revenue expectations despite challenges, demonstrates its resilience and market strength.
- The substantial cash reserves of approximately $953.8 million position Sarepta favorably for strategic investments in approved treatments and the development of its siRNA pipeline in 2026.
Sarepta Therapeutics concluded 2025 on a high note, overcoming hurdles and achieving significant revenue growth. The company's strong financial position and strategic focus on expanding its product portfolio with innovative therapies set a positive trajectory for 2026 and beyond.